Raber-Durlacher, Judith E.
Treister, Nathaniel S.
Zadik, Yehuda
Dean, David R.
Miranda-Silva, Wanessa
Fregnani, Eduardo R.
Epstein, Joel B.
Elad, Sharon
Article History
Received: 7 June 2024
Accepted: 24 June 2024
First Online: 25 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: The MASCC/ISOO OCSG Statements have been developed to facilitate the expert-opinion based management of oral complications of cancer and cancer therapy where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. The Statement authors and the MASCC/ISOO do not guarantee or take responsibility for clinical outcomes in individual patients.
: Y. Zadik, N. S. Treister, D.R. Dean, W. Miranda e Silva, E.R. Fregnani, and S. Elad reported no relevant financial or non-financial interests to disclose within the last 3 years of beginning the work and none outside the 3-year time frame that could reasonably be perceived as influencing the submitted work. J.E. Raber-Durlacher received in kind support from THOR Photomedicine Inc. J.B. Epstein is a consultant for Galera Therapeutics, Janssen Biopharmaceuticals, Nestle Healthcare, and Tosk Inc. J.B. Epstein is a consultant and has funded research from SaNOtize Research and Development Corp. J.B. Epstein is associated Editor-in-Chief for <i>Supportive Care in Cancer</i>.